Browse by category

The first patient has been dosed in Syntis Bio's the Phase 1/1b SYNTIETY-1 clinical trial of SYNT-101, the company’s lead investigational program for the treatment of obesity. SYNT-101 is designed as a once-daily oral pill that redirects nutrient absorption past the small intestine’s duodenum, mimicking the effects of gastric bypass surgery. SYNT-101 works by transiently blocking nutrient absorption in the duodenum, the upper part of the small intestine, and redirecting nutri

The FDA has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System (AGBS), featuring the Allurion Smart Capsule. The Allurion Program is a weight-loss platform that combines the FDA PMA approved Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, with the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers featuring the Iris AI platform, Allurion Insights for healthcare providers, and the Allurion

A qualitative narrative review by researchers at St George’s University, St George’s, Grenada, has reported that endoscopic sleeve gastroplasty (ESG) represents a safe, minimally invasive and versatile intervention for obesity, occupying a unique position between conservative medical therapy and surgical bariatric procedures. According to the researchers, their review highlights ESG’s ability to produce meaningful weight loss and metabolic improvements while minimising proced

Nonmedical factors drive up to 60 percent of health outcomes, and for people with type 2 diabetes (T2D), social determinants of health factors like poverty, food insecurity, and unstable housing can derail even the best treatment plans. Now, a long-term study led by investigators at Joslin Diabetes Center finds that bariatric metabolic surgery is more effective at glycaemic and weight control than medical and lifestyle interventions for people with T2D, even in the setting of

At Roxborough Memorial Hospital in Philadelphia, surgeon Piotr Krecioch has his hands full launching a program offering surgical interventions to treat obesity. One in three Philadelphians are living with obesity, putting them at higher risk of chronic conditions like diabetes and heart disease, but these days fewer are seeking the bariatric surgical procedures long considered a leading medical treatment for the condition. "I'm trying to start a bariatric program at probably

The European Commission has granted final approval of a higher 7.2 mg maintenance dose of Wegovy (semaglutide) for adults who may need extra help losing weight. It is now approved in all 27 countries in the European Union. This gives doctors another option to help adults who need more weight loss after being on the 2.4 mg dose. The approval is based on a positive opinion from the European Medicines Agency’s scientific committee (CHMP) on 12 December 2025. The approval means t